Binge Eating Disorder Market By Product (Antidepressants, Anticonvulsants, Others) By Application (Retail Pharmacies, and Hospital Pharmacies, Others) Regional Analysis & Forecast - 2026

Binge Eating Disorder (BED) is more known or symptomized by the irresistible urge of overeating or uncontrollable feeling to eat large amounts of food and unable to stop the same. The disorder often leads to unwanted weight gain or obesity. Even though the exact cause of the disorder is not known, other factors like biological (hormonal abnormalities), psychological and traumatic situations can trigger compulsive eating. Consequences of the disorder lead to other serious complications like diabetes, cardiovascular diseases, gastrointestinal diseases, joint pains, etc.  Experts understand that BED generally occurs along with depression, anxiety disorder or substance abuse or indeed lifestyle stress. Thus, a proper diagnosis and treating the root cause becomes important in the treatment. Similar to other eating disorders, people with BED can take decades to overcome without treatment, and of those who do receive treatment, more commonly takes 3−7 years but some may recover in less than a year.

Market Overview

Currently, BED is the most common eating disorder in the US. It is mostly tends to appear in late adolescence or adulthood that is later than anorexia nervosa (AN) and bulimia nervosa (BN) presented typically. Cognitive behavioral therapy (CBT) is known to be the first-line treatment for BED, but pharmacotherapy is also prepared as an adjunctive or alternative treatment to CBT. At present only one pharmacotherapy is approved for the treatment of BED, Shire’s Vyvanse (lisdexamfetamine dimesylate), which received an approved label expansion to include BED by the FDA in 2015. However, other therapeutics including antidepressants, anticonvulsants, and obesity drugs, are commonly used as off-label treatments.

Currently, psychotherapy is a primary dependent treatment that addresses the underlying cause associated with the urge and focuses on the same. Availability of a smaller number of products for the treatment of BED like Vyvanse from the Shire or current dominance of off label use has provoked many pharmaceutical companies and also the academic institutions to develop drugs. Increased cases and awareness of the condition has fuelled the need for the focus of the development of more drugs.  Dasotraline from Sunovion is expected to file for NDA. Sunovion Pharmaceuticals is following in Vyvanse’s footsteps by taking dasotraline, their norepinephrine, dopamine and 5-HT reuptake inhibitor currently filed for ADHD, into Phase III trials for binge eating disorder. Naloxone nasal spray of Opiant Pharmaceuticals which is an opioid receptor antagonist is in phase 2 stage of development that aims to treat the uncontrollable bingeing habit. Also, Roche has entered into the development of RO5256390, which is at present in the preclinical stage of development. Clinical trial activity in the eating disorders is dominated by completed trials. The Shire found to has the highest number of completed clinical trials for eating disorders, with five trials.

The market of BED is challenging as not many changes have been noticed and very few products are in late stage of development. A major challenge for the drug makers if to unravel the psychological and metabolic relation of the condition. The major problem faced by practitioners is the identification of the disorder. With an increase in awareness about the disorder, more number of cases are coming to light. Most of the Researchers and practitioners are trying for the development of new drugs and therapies to cure the same. With an increase in connectivity and access to information, patients from different countries have too started to look for the treatment options.

Key Developments

• In Feb 2019, Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa.


• In Feb 2019, a new study in children that are aged 6 to 12 years of dasotraline, a promising new treatment for ADHD, showed significant improvement in the efficacy of the treatment of ADHD compared to placebo beginning at 1st week and is continuing throughout the study.

Segmentation   

Binge Eating Disorder market is segmented on the basis of product, application, and region.

Product: Antidepressants, Anticonvulsants, and Anti-obesity Medications

End User: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies

Region: The Middle East and Africa (Egypt, and GCC Countries), South America (Brazil etc.), Europe (Turkey, Germany, Russia UK, Italy, France, etc.), North America (the United States, Mexico, and Canada.), Asia-Pacific (Vietnam, China, Japan, Philippines, Korea,Malaysia, Thailand, India, Indonesia, and Australia.)

Emerging companies and the recent entrants include Chronos Therapeutics, F. Hoffmann-La Roche, Heptares Therapeutics, Novo Nordisk, Omeros, Opiant Pharmaceuticals, Polleo Pharma, Shire, Sunovion Pharmaceuticals.